Friday, October 21, 2022 10:18:01 PM
Scripts for week ending October 14, 2022
Drug Industry TRx: -1.9% w/w; +7.0% y/y
Vascepa
TRx 62,515; -3.0% (-1,962) w/w; -20.9% y/y
NRx 28,052; -5.2% (-1,549) w/w; -21.0% y/y
Ref 34,463; -1.2% (-413) w/w; -20.9% y/y
Fake Vascepa
TRx 39,895; -0.7% (-263) w/w; As % of total V: 39.0%
NRx 18,936; -4.3% (-860) w/w; As % of total V: 40.3%
Ref 20,958; +2.9% (+587) w/w; As % of total V: 37.8%
Fake Vascepa by Manufacturer
Hikma - TRx 14,614; +617 w/w; Generic share 36.6%; Total V share 14.3%
Reddy - TRx 17,713; -928 w/w; Generic share 44.4%; Total V share 17.3%
Apotex - TRx 7,379; +25 w/w; Generic share 18.5%; Total V share 7.2%
Teva - TRx 189; +24 w/w; Generic share 0.5%; Total V share 0.2%
Vascepa + Fake Vascepa
TRx 102,410; -2.1% (-2,225) w/w; +3.0% y/y
NRx 46,988; -4.9% (-2,409) w/w; -0.3% y/y
Ref 55,042; +0.3% (+184) w/w; +5.9% y/y
Lovaza (Fake & Brand)
TRx 62,249; -3.2% (-2,042) w/w; +0.8% y/y
NRx 30,272; -2.0% (-607) w/w; +1.6% y/y
Ref 31,977; -4.3% (-1,445) w/w; +0.0% y/y
Drug Industry TRx: -1.9% w/w; +7.0% y/y
Vascepa
TRx 62,515; -3.0% (-1,962) w/w; -20.9% y/y
NRx 28,052; -5.2% (-1,549) w/w; -21.0% y/y
Ref 34,463; -1.2% (-413) w/w; -20.9% y/y
Fake Vascepa
TRx 39,895; -0.7% (-263) w/w; As % of total V: 39.0%
NRx 18,936; -4.3% (-860) w/w; As % of total V: 40.3%
Ref 20,958; +2.9% (+587) w/w; As % of total V: 37.8%
Fake Vascepa by Manufacturer
Hikma - TRx 14,614; +617 w/w; Generic share 36.6%; Total V share 14.3%
Reddy - TRx 17,713; -928 w/w; Generic share 44.4%; Total V share 17.3%
Apotex - TRx 7,379; +25 w/w; Generic share 18.5%; Total V share 7.2%
Teva - TRx 189; +24 w/w; Generic share 0.5%; Total V share 0.2%
Vascepa + Fake Vascepa
TRx 102,410; -2.1% (-2,225) w/w; +3.0% y/y
NRx 46,988; -4.9% (-2,409) w/w; -0.3% y/y
Ref 55,042; +0.3% (+184) w/w; +5.9% y/y
Lovaza (Fake & Brand)
TRx 62,249; -3.2% (-2,042) w/w; +0.8% y/y
NRx 30,272; -2.0% (-607) w/w; +1.6% y/y
Ref 31,977; -4.3% (-1,445) w/w; +0.0% y/y
Recent AMRN News
- Amarin Highlights New REDUCE-IT Analysis Showing Risk-Weighted ApoB May Improve Cardiovascular Risk Detection (AMRN) • IH Market News • 05/27/2026 03:24:38 PM
- New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia • GlobeNewswire Inc. • 05/27/2026 12:00:00 PM
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
